RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

This study is looking back at medical records to see how well a drug called mosunetuzumab worked for adults with follicular lymphoma that came back or didn't respond to at least two other treatments. The drug was given through a special program for patients who had no other good …

This study is testing whether a new drug combination (zanubrutinib plus an antibody) works better than the current standard treatment (lenalidomide plus rituximab) for people whose follicular or marginal zone lymphoma has returned or stopped responding to prior therapy. It will e…

This study is testing whether a new drug combination works better than the current standard treatment for two types of lymphoma that have returned or stopped responding to prior therapy. It will involve about 470 adults with relapsed or hard-to-treat follicular lymphoma or margin…

This large, late-stage trial is testing whether adding a new drug called tazemetostat to a standard two-drug treatment helps people with follicular lymphoma live longer without their cancer getting worse. The study is for adults whose lymphoma has returned or stopped responding t…

This study is testing whether a combination of four existing drugs can help control follicular lymphoma that has returned or stopped responding to previous treatments. It will involve about 33 adults whose cancer has come back after at least two prior therapies. The main goal is …